Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin.
作者信息
Thachil Jecko
机构信息
Department of Haematology, Manchester University Hospitals, Manchester, UK.
出版信息
J Thromb Haemost. 2020 Sep;18(9):2424-2425. doi: 10.1111/jth.14933. Epub 2020 Jun 25.
Abstract
摘要
相似文献
1
Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin.肝素抗凝与非抗凝特性的临床鉴别
J Thromb Haemost. 2020 Sep;18(9):2424-2425. doi: 10.1111/jth.14933. Epub 2020 Jun 25.
2
Anticoagulant approach in COVID-19 patients with cerebral venous thrombosis.新冠病毒肺炎合并脑静脉血栓形成患者的抗凝治疗方法
J Stroke Cerebrovasc Dis. 2020 Dec;29(12):105222. doi: 10.1016/j.jstrokecerebrovasdis.2020.105222. Epub 2020 Aug 3.
3
Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients.肝素在治疗新冠肺炎患者中的抗凝和抗心律失常作用。
J Thromb Haemost. 2020 Aug;18(8):2073-2075. doi: 10.1111/jth.14902.
4
Heparin failure and COVID-19: Should we explore other anticoagulants? An observational report regarding in-vitro recovery of anticoagulant action in COVID-19 patients in intensive care.肝素失效与新冠病毒病：我们是否应探索其他抗凝剂？一份关于重症监护病房新冠病毒病患者抗凝作用体外恢复情况的观察报告
Thromb Res. 2020 Nov;195:226-227. doi: 10.1016/j.thromres.2020.08.010. Epub 2020 Aug 9.
5
Comprehensive Landscape of Heparin Therapy for COVID-19.肝素治疗 COVID-19 的全面概况。
Carbohydr Polym. 2021 Feb 15;254:117232. doi: 10.1016/j.carbpol.2020.117232. Epub 2020 Oct 22.
6
Non-anticoagulant heparin derivatives for COVID-19 treatment.用于 COVID-19 治疗的非抗凝肝素衍生物。
Int J Biol Macromol. 2023 Jan 31;226:974-981. doi: 10.1016/j.ijbiomac.2022.12.090. Epub 2022 Dec 14.
7
Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients.在 SARS-CoV-2 住院患者中，将口服抗凝剂转换为普通肝素。
Intern Emerg Med. 2020 Aug;15(5):751-753. doi: 10.1007/s11739-020-02331-1. Epub 2020 Apr 15.
8
[COVID-19-associated coagulopathy].[新型冠状病毒肺炎相关凝血病]
Rinsho Ketsueki. 2021;62(8):1236-1246. doi: 10.11406/rinketsu.62.1236.
9
COVID-19 Experience in Hemodialysis Patients: A Cue for Therapeutic Heparin-Based Strategies?COVID-19 疫情下血液透析患者的应对策略：肝素类药物治疗的新契机？
Nephron. 2020;144(8):383-385. doi: 10.1159/000508638. Epub 2020 Jun 11.
10
Heparin and SARS-CoV-2: Multiple Pathophysiological Links.肝素与 SARS-CoV-2：多种病理生理学关联。
Viruses. 2021 Dec 11;13(12):2486. doi: 10.3390/v13122486.
引用本文的文献
1
Management of Therapeutic-intensity Unfractionated Heparin: A Narrative Review on Critical Points.治疗强度普通肝素的管理：关键点的叙述性综述
TH Open. 2024 Oct 17;8(3):e297-e307. doi: 10.1055/a-2359-0987. eCollection 2024 Jul.
2
Heparin mimetics as potential intervention for COVID-19 and their bio-manufacturing.肝素模拟物作为COVID-19的潜在干预手段及其生物制造
Synth Syst Biotechnol. 2023 Mar;8(1):11-19. doi: 10.1016/j.synbio.2022.10.002. Epub 2022 Oct 23.
3
Heparin and Related Substances for Treating Diabetic Foot Ulcers: A Systematic Review and Meta-Analysis.肝素及相关物质治疗糖尿病足溃疡：系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2022 Feb 24;13:749368. doi: 10.3389/fendo.2022.749368. eCollection 2022.
4
How we approach thrombosis risk in children with COVID-19 infection and MIS-C.我们如何应对新冠病毒感染和儿童多系统炎症综合征患儿的血栓形成风险。
Pediatr Blood Cancer. 2021 Jul;68(7):e29049. doi: 10.1002/pbc.29049. Epub 2021 May 6.
5
Breakthrough venous thromboembolic events in five patients with COVID-19 on direct oral anticoagulants.五例 COVID-19 患者使用直接口服抗凝剂后出现突破性静脉血栓栓塞事件。
J Clin Pharm Ther. 2021 Apr;46(2):519-523. doi: 10.1111/jcpt.13311. Epub 2020 Nov 20.
6
The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID-19 Patients: A Retrospective Cohort Study.低分子量肝素减轻重症 COVID-19 患者细胞因子风暴的潜力：一项回顾性队列研究。
Clin Transl Sci. 2020 Nov;13(6):1087-1095. doi: 10.1111/cts.12880. Epub 2020 Oct 15.
本文引用的文献
1
Using heparin molecules to manage COVID-2019.使用肝素分子来应对2019冠状病毒病。
Res Pract Thromb Haemost. 2020 Jun 9;4(4):518-523. doi: 10.1002/rth2.12353. eCollection 2020 May.
2
Heparin - An old drug with multiple potential targets in Covid-19 therapy.肝素——一种在新冠病毒治疗中有多种潜在靶点的老药。
J Thromb Haemost. 2020 Sep;18(9):2422-2424. doi: 10.1111/jth.14898. Epub 2020 Aug 27.
3
Mild or Moderate Covid-19.轻度或中度新冠病毒感染
N Engl J Med. 2020 Oct 29;383(18):1757-1766. doi: 10.1056/NEJMcp2009249. Epub 2020 Apr 24.
4
More than an anticoagulant: Do heparins have direct anti-inflammatory effects?不仅仅是一种抗凝剂：肝素是否具有直接抗炎作用？
Thromb Haemost. 2017 Feb 28;117(3):437-444. doi: 10.1160/TH16-08-0620. Epub 2016 Dec 15.
5
Heparin-binding protein is important for vascular leak in sepsis.肝素结合蛋白对脓毒症时的血管渗漏很重要。
Intensive Care Med Exp. 2016 Dec;4(1):33. doi: 10.1186/s40635-016-0104-3. Epub 2016 Oct 4.
6
The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis.肝素在脓毒症患者中的疗效与安全性：一项系统评价和荟萃分析。
Crit Care Med. 2015 Mar;43(3):511-8. doi: 10.1097/CCM.0000000000000763.
7
The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis.实验性脓毒症中肺内皮糖萼调节中性粒细胞黏附和肺损伤。
Nat Med. 2012 Aug;18(8):1217-23. doi: 10.1038/nm.2843. Epub 2012 Jul 22.
8
Inflammation induces hemorrhage in thrombocytopenia.炎症在血小板减少症中诱发出血。
Blood. 2008 May 15;111(10):4958-64. doi: 10.1182/blood-2007-11-123620. Epub 2008 Feb 6.
Zotero 插件